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Abstract
Background: Urate-lowering therapy (predominantly allopurinol) is highly effective as a treatment for gout, but its wider long-term effects remain unclear. This systematic review and meta-analysis aimed to ascertain the association between allopurinol use in patients with gout and mortality. 
Method: MEDLINE, EMBASE, CINAHL and the Cochrane Library were searched from inception to August 2018. Articles eligible for inclusion used a cohort design and examined cardiovascular or all-cause mortality in patients diagnosed with gout and prescribed allopurinol. Information on study characteristics, design, sample size and mortality risk estimates were extracted. Article quality was assessed using the Newcastle-Ottawa Scale. Included articles were described in a narrative synthesis and (where possible) risk estimate data were pooled. 









Conclusions: There was no significant association between all-cause mortality and allopurinol use in people with gout. However, the number of included studies was small, suggesting that further studies are needed.
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Significance and Innovations
 We found no significant association between all-cause mortality and allopurinol use in people with gout.
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associated with a 25% lower risk of mortality during follow-up compared with untreated patients (13, 14).Despite guidelines recommending earlier prescription of ULT (8, 9) and the reported benefits on comorbidities, the use of allopurinol to treat gout remains sub-optimal. Though the reasons behind this are multifaceted, one contributing factor relates to the apprehension of patients and clinicians to initiate life-long treatment without a clear understanding of the long-term effects (1). As the overall balance of potential benefit and risk in the role of allopurinol on mortality in patients with gout remains unclear, this systematic review and meta-analysis examined the association between the use of allopurinol in patients with gout and cardiovascular or all-cause mortality.
Materials and MethodsA systematic review of research literature was conducted. Medical literature databases were searched to identify articles which included patients with gout treated using allopurinol and had reported the risk of cardiovascular or all-cause mortality in their sample. Meta-analysis was used to determine pooled risk estimates of mortality. The protocol for this systematic review and meta-analysis was registered on PROSPERO (ID CRD42017056011) and the systematic review was undertaken following PRISMA guidelines.









© 2020 The Authors. Arthritis Care & Research published by Wiley Periodicals LLC on behalf 
of American College of Rheumatology 
 
were no language restrictions; however, if translational facilities were not available for an article, they were excluded. 
Data extractionData were extracted by two authors (CAH, JAP) with the main data including; demographic information (age, sex, country of origin etc), study sample size, numbers of patients with gout, study setting (e.g. primary care), exposures (e.g. allopurinol), mortality outcome (e.g. all-cause, cardiovascular), definition of gout and method of adjusted risk estimates regarding the association between gout treated with allopurinol and cardiovascular and all-cause mortality risk estimates.
Quality AssessmentAll articles finally included in the systematic review were quality appraised independently by two assessors (CAH, JAP). Any disagreement on initial scoring was discussed, and if this could not be agreed upon, the decision was arbitrated by a third reviewer (ER). Methodological quality was assessed using the Newcastle-Ottawa Scale (NOS) for cohort studies (15).  
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From 362 articles identified by the initial literature search, 90 duplicates were removed. The titles of the remaining 272 articles were screened, after which 37 articles remained. After an abstract review of these, 32 articles were excluded. The full text of the remaining 5 articles were reviewed in full and a final four articles were deemed to fulfil the inclusion criteria (Figure 1). 









© 2020 The Authors. Arthritis Care & Research published by Wiley Periodicals LLC on behalf 
of American College of Rheumatology 
 
initial time-period immediately after gout diagnosis, reducing the possibility of conferring an unfair survival advantage on the allopurinol treated group. Coburn et al. used two models; in model 1, they followed up patients from exposure, and in model 2, they followed up patients after a 2-year landmark.
Quality AssessmentAll four articles included representative patients with gout, assessed exposures and outcomes using secure methods (medical records) and employed appropriate methods to compare subjects, with and without gout, to avoid confounding by indication affecting the veracity of results, with all four studies employing propensity score matching.  Three of the four papers also employed methods to attempt to negate immortal time bias; Chen et al. used time-index matching between patients and controls and Coburn et al. utilised an analytical method which involved only following up patients alive two years after allopurinol initiation. Kuo et al. employed a landmark analysis method which only followed up patients alive after one-year post-allopurinol initiation and then three years after initiation. Loss-to-follow-up was minimal and accounted for in analyses.
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significant HR for model 2 (inclusion of 2-year landmark analysis, 1.05 (95% CI 0.96-1.15)). However, as these HR were based on stratification by dose, their inclusion in the pooled analysis was not possible. The pooled adjusted HR for all-cause mortality calculated from the three applicable cohorts was 0.80 (95% CI 0.60-1.05), heterogeneity was statistically significant (87.6%, p<0.001) (Figure 2). 
Risk of cardiovascular mortalityChen et al. reported a protective effect of allopurinol on cardiovascular mortality, finding a hazard ratio in patients with gout treated with allopurinol of 0.37 (95% CI 0.01-0.48) compared to non-allopurinol users. Coburn et al. initially reported an association between increased cardiovascular-related mortality in those with escalated allopurinol dose compared to those with a stable dose for model 1 (HR 1.08, 95% CI 0.97– 1.21), but no association remained in model 2 (1.05 (95%CI 0.92-1.20)). Due to the sparsity of data related to cardiovascular mortality we were unable to conduct pooled analysis for this outcome.
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This is the first systematic review to examine the association between patients with gout treated with allopurinol and cardiovascular or all-cause mortality. Our search criteria were extensive (not limited by language) and included cohort studies from large, nationally representative samples using data over similar time periods to provide a more generalisable picture of the role of allopurinol on mortality in patients with gout. Risk estimates for all-cause mortality from different studies were pooled. The principal limitations of our review are the small number of articles available and statistical heterogeneity in the pooled analysis. However, despite the low number of studies,  those included in this systematic review are of high methodological quality, having factored in methods for avoiding immortal time bias and confounding by indication.
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Table 1: The characteristics, demographics and risk values of the study sample used in each included articleAuthor, year Population Study period Sample Size Incident gout(n) Males(%) Mean Age(SD) Adjusted Hazard Ratios(95% CI)
Chen et al. (2015) MJ Health Screening Centre Database, Taiwan 1997-2002 1,457 286 89 52.7 (15.4) 0.39 (0.22-0.70)
Coburn et al. (2016) US Department of Veterans Affairs Health Administration (VHA) 1999-2010 111,694 6,428^ 99.7 64.4 (10.5) 1.05 (0.96-1.15)*
Dubreuil et al. (2015) The Health Improvement Network (THIN), UK 2000-2010 9,590 483 69 67 0.81 (0.70-0.92)
Kuo et al. (2015) Clinical Practice Research Datalink (CPRD), UK 1995-2013 19,549 3519 72 64 (52-73)** 0.99 (0.87-1.12)***1.01 (0.92-1.09)****
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Figure 1: Flow diagram of the number of articles at each stage of the search and screening process 
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